Target intelligence / Profile preview

UBX domain protein 2A (UBXN2A)

Target: UBXN2A
Molecular classification: Adaptor protein (cofactor for ATPase), Ubiquitin-binding protein, Protein containing UBX domain (ubiquitin regulatory X domain), AAA ATPase cofactor, Cytoplasmic and nuclear protein

Overview

UBX domain protein 2A (UBXN2A) is a cytoplasmic and nuclear cofactor containing a ubiquitin regulatory X (UBX) domain. It acts as an adaptor for the AAA ATPase p97/VCP, participating in the ubiquitin-proteasome system and modulating the degradation of proteins integral to cell survival and tumor suppression, such as mot-2 and p53. UBXN2A is implicated in autophagy, ERAD processes, and acetylcholine receptor trafficking. Experimental evidence suggests it plays a role in inhibiting tumor growth and promoting apoptosis, particularly in colon cancer models. Its protein interactions position it as a central regulator of quality control pathways vital to cancer biology and neurodegenerative disorders.

Other names: UBXN2AUBX domain-containing protein 2AUBX2AUBXD4MGC138202

Mechanism of action

UBXN2A's mechanism of action involves: Modulation of p53 availability by disrupting mot-2/p53 interaction; Regulation of ubiquitin-mediated proteasomal degradation of substrate proteins; Modulation of acetylcholine receptor trafficking via interaction with STUB1 and VCP.

Biological functions

Ubiquitin bindingProtein degradation via the ubiquitin-proteasome systemNegative regulation of endoplasmic reticulum-associated degradation (ERAD) pathwayPositive regulation of protein catabolic processesRegulation of membrane traffickingRegulation of acetylcholine receptor transportRegulation of tumor suppressor p53 activity

Disease associations

Cancer (with experimental evidence for roles in colon adenocarcinoma and impact on tumor growth, reproduction, and metastasis)Neuropathy, hereditary motor and sensory, Okinawa type

Safety considerations

As the protein is involved in fundamental cellular processes such as protein homeostasis and cell death, targeting it could potentially lead to off-target toxicity, especially in tissues with high turnover or high UBXN2A expression, but no specific safety concerns have been reported in clinical contexts.

Biomarkers

Protein expression level may serve as a biomarker in colon adenocarcinoma (low levels in tumors, upregulated upon therapeutic intervention); however, no clinically validated biomarkers reported for UBXN2A specifically.

Beyond the preview

Go deeper on UBX domain protein 2A (UBXN2A).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Explore the programs pursuing this target and their development progress.

Drug candidates
Developers
Development stage

Clinical trials

Follow the clinical studies evaluating therapies directed at this target.

Trial design
Status
Readouts

Competitive landscape

Compare approaches across drug candidates, modalities, and indications.

Programs
Modalities
Indications

Literature & evidence

Investigate the research and source evidence behind target biology and development.

Publications
Sources
Analysis

Patents

Explore patent activity around therapies and technologies addressing this target.

Patents
Assignees
Technologies

Research & analysis

Connect target biology, drug development, and emerging evidence in your research.

Biology
Development news
Analysis

Bring the full picture into focus.

See how Gosset can support your research on UBX domain protein 2A (UBXN2A).

Explore the full profile